Toggle Nav
mobile icon
My Cart
Close
  • Menu
  • Setting
  • Home
  • Signaling Pathways

Signaling Pathways

6 Items

per page
  1. SB202190 (FHPI)
    A1632 SB202190 (FHPI)
     5 Citation
    Target: p38
    Summary: P38 MAPK inhibitor
  2. LY2228820
    A5566 LY2228820
     1 Citation
    Target: p38
    Summary: P38 MAP kinase inhibitor
      ≥30.65 mg/mL
  3. Pimasertib (AS-703026)
    A5573 Pimasertib (AS-703026)
    Target: MEK
    Summary: MEK1/2 inhibitor
      ≥21.55 mg/mL
  4. MEK162 (ARRY-162, ARRY-438162)
    A1947 MEK162 (ARRY-162, ARRY-438162)
    Target: MEK
    Summary: MEK1/2 inhibitor,potent and selective
      insoluble in H2O; insoluble in EtOH; insoluble in DMSO
  5. LY3009120
    A8716 LY3009120
    Target: Raf
    Summary: pan-RAF and RAF dimer inhibitor
      insoluble in H2O; insoluble in EtOH; ≥4.25 mg/mL
  6. Trametinib (GSK1120212)
    A3018 Trametinib (GSK1120212)
     7 Citation
    Target: MEK
    Summary: MEK1 and MEK2 inhibitor, potent and selective
      insoluble in H2O; insoluble in EtOH; ≥15.38 mg/mL

6 Items

per page
Relate Categories
Now Shopping by
  1. Category MAPK Signaling Remove This Item
  2. Reported Experiments Cell Experiments Remove This Item
  3. Related Disease Colorectal Cancer Remove This Item
Clear All